A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The ...

Discover surprising truths about blindness, from the spectrum of visual impairment to revolutionary treatments and adaptive ...

Medtech: In the 21st century, ‘Artificial Intelligence (AI)’ is not a buzzword—it is the brain of modern medicine. As the ...

Dr. Michael Kapusta, MD, FRSCS, Ophthalmologist, talks about advanced (proliferative) diabetic retinopathy and pars plana ...

Verseon is combining AI with deep quantum modeling, which allows for stronger models of protein-drug interactions. CEO Adityo ...

A group of 18 African ophthalmologists have successfully completed a one-year specialized training program in Diabetic ...

Out of this, 4% have vision-threatening diabetic retinopathy (VTDR), which causes ... inadvertently allowing it to progress to an advanced stage. Dr Padmaja Kumari Rani, Network Associate Director ...

Diabetic retinopathy poses a significant threat to public health ... packaged in the Mobile Examination Center (MEC), stored at 2–8°C, and shipped to the Advanced Research Diagnostic Laboratory (ARDL) ...

Vantage Biosciences has successfully dosed the first patient in its phase 2 clinical study evaluating VX-01, an oral therapy for the treatment of nonproliferative diabetic retinopathy (NPDR).

The global optical coherence tomography (OCT) devices market is witnessing remarkable growth and is anticipated to reach a market value of USD 2.87 billion by 2032, up from USD 1.30 billion in 2023.